Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT05892952
Recruiting Observational

IONA Longitudinal Cohort Study

NCT05892952 · tracked via the Priya Life Science UK tracker
Sponsor
Brain Health Scotland Life Sciences Ltd
Phase
Observational
Started
2023-12-21
Last updated
2025-09-19

Condition(s) studied

Alzheimer DiseaseDementia

Study summary

Understanding more about how diseases that cause dementia develop is critical as the number of people living with, or affected by, dementia in Scotland continues to grow. The IONA Longitudinal Cohort Study (LCS) has been set up to gather information about people's cognitive health (their memory and thinking abilities), their lifestyle and health risk factors for future dementia (such as hearing loss and obesity), genetics and disease biomarkers, over a number of years. The IONA LCS has three main objectives: Firstly to develop this cohort that is well characterised (also known as being "well-phenotyped") that represent the Scottish population (taking into consideration age, sex, ethnicity and education). The second objective is to use this data to build disease models to better understand trajectories of diseases, and identify any sub-populations who have different (i.e. better, worse) disease trajectories. Finally the third objective for IONA LCS is to offer people an optional consent to hear about future studies they may be interested in taking part in.

Eligibility

Sex
ALL
Min age
50 Years
Max age
120 Years
Healthy volunteers
No
* Age at least 50 years. * Living in Scotland. * Able to read and write and with minimum 7 years of formal education. * Have a study partner who is aged 18 years or older. * Have capacity to provide informed consent at baseline. * Able to speak English to a level where the cognitive assessments can be completed.

Primary outcome measure(s)

  • Change over time on the IONACog (a composite neuropsychological battery) — 10 years
  • (Enhanced Phenotype only) Change over time in cerebrospinal fluid amyloid beta-42 — 10 years
  • (Enhanced Phenotype only) Change over time in cerebrospinal fluid phosphorylated tau 181 — 10 years
  • (Enhanced Phenotype only) Change over time in cerebrospinal fluid total tau — 10 years

Trial sites (1)

FacilityCityRegionStatus
Scottish Brain Sciences Arran Facility Edinburgh Lothian Recruiting

Other trials for the same condition

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Active, not recruiting
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) Active, not recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) Recruiting
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05892952 on ClinicalTrials.gov ↗ ← All trials in the UK